The cap will reduce out-of-pocket spending for potentially millions of older Americans in Medicare Part D, which covers pharmacy or mail-order prescriptions. The cap doesn't apply to drugs administered by doctors. The cap is part of the Inflation Reduction ...

Medicare enrollees will not have to pay more than $2,000 in out-of-pocket drug expenditures — and that could lead to huge savings, according to one analysis.

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, starting in 2027. These medications, used for conditions like diabetes, weight loss, and asthma, accounted for $41 billion in Medicare spending last year. Novo Nordisk’s drugs alone cost $14.4 billion.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Medicare Payment Advisory Commission recommends tying physician payment update to care cost growth; AMA calls for Congress to act on analysis.

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule. Administration officials did

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

More than four out of five jobs filled in the past two years have been in public service, health and education.

Although Medicare enrollees typically don't pay a premium for Part A, which covers hospital care, there's a cost for being admitted to the hospital. In 2025, you'll face a $1,676 inpatient deductible, up from $1,632 in 2024.